The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

LEQEMBI ® [ (lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer's disease (AD). Treatment with LEQEMBI should be initiated in patients with mild ...

Marketing for the popular nicotine pouch product, Zyn, has been approved by the U.S. Food and Drug Administration to help ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The FDA approved 50 novel drugs that contained an active ingredient not previously approved by the agency, whilst the EMA authorised 46 new medicines. Whilst racking up 50 novel drug approvals ...

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration ... who have not responded adequately to at least two oral antidepressants. The company hailed the approval as ...